BSD Med Corp. (fka PRSNQ)

[mightymoe]

MOST Recent PRSN news::1,2,3-4

1

Perseon Announces New Data for MicroThermX(R) in the Treatment of Large Liver Metastases From Colorectal Cancer and Large Hepatocellular Carcinoma From the 2015 Congress of Italian Society of Oncological Surgery (SICO) Conference

Perseon Corporation
11 hours ago
GlobeNewswire http://finance.yahoo.com/news/perseon-announces-data-microthermx-r-131500888.html
????

SALT LAKE CITY, Sept. 15, 2015 (GLOBE NEWSWIRE) -- Perseon Corporation (PRSN) ("Perseon" or the "Company") today announced that data supporting the use of the company's cutting edge microwave ablation technology, MicroThermX, was presented at the 38th Congress of Italian Society of Oncological Surgery (SICO) in Naples, Italy from September 9 -- 12, 2015. The data included two posters, which looked at the use of multiple antennas in the treatment of large liver metastases from colorectal cancer and large hepatocellular carcinoma.

"These studies are just two examples that physicians are recognizing the unique properties of MicroThermX's Synchronous Wave Alignment Technology in the treatment of tumors, especially large tumors where energy ablation was previously viewed as ineffective," said Brian Meltzer, M.D., Chief Medical Officer and Vice President of Business Development. "These data reinforce MicroThermX as a safe and efficacious treatment option with low complication rates and the potential to reduce costly surgical resections of cancer."

Ablation of Large Liver Metastases from Colorectal Cancer Using Synchronous Insertion of Multiple Microwave Antennas evaluated the use of percutaneous energy ablation for the treatment of large (> 3 cm) colorectal cancer metastases (CRCmets) of the liver. Findings of this study show that there was a low complication rate with treatments and a high rate of complete necrosis. Complete response was shown in 92 percent (11/12) of patients treated with CRCmets.
Ablation of Large Hepatocellular Carcinoma (HCC) Using a New Multiple Antenna Microwave Device: Case Series evaluated the use of MicroThermX to achieve large volumes of necrosis in (HCC) by synchronous insertion and activation of multiple microwave antennas. Results showed that MicroThermX used in the treatment of (HCC) was safe and efficacious, with complete necrosis in 80 percent of HCC cases (8/10).
These data come at a time when Perseon continues to push for clinical results to reflect the safety and efficacy of microwave ablation, and to show the health economic advantages of using multiple, synchronized wave antennas at the time of the initial procedure.

About Perseon Corporation

Perseon Corporation invests its resources in fighting humanity's worst disease -- cancer. Perseon's people are dedicated to finding innovative technologies and means to deliver energy ablation solutions to healthcare providers and patients around the world. MicroThermX treats soft tissue tumors with precision-focused energy, expanding the options and broadening the opportunities for cancer treatment.

About MicroThermX

Perseon's energy ablation system, MicroThermX, has been developed as a stand-alone therapy that employs precision-guided microwave energy to ablate (burn) and destroy soft tissue. Perseon has developed extensive intellectual property and has established distribution in the United States, Europe and Asia.

Treatment sites include tumor ablation of the liver, kidney, brain, bone, lung, and other soft-tissue locations.

Forward-Looking Statements

Statements contained in this press release that are not historical facts, including statements relating to our focus on microwave ablation to create stockholder value and pursuit of our strategic plans are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties, including the risk that for a variety of reasons we may not be able to execute on our strategic plans, and other risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date, except as required by law.

Contact:
Jennifer R. Hoglin
Vice President of Global Marketing
Phone: [phone]
Email: [e-mail]

2

Perseon Announces the Initiation of the First Multi-Organ in vivo Ablation Zone Study for MicroThermX(R) in Laparoscopic and Open Approaches

Perseon Corporation
August 31, 2015 9:15 AM
GlobeNewswire : http://finance.yahoo.com/news/perseon-announces-initiation-first-multi-131500072.html

SALT LAKE CITY, Aug. 31, 2015 (GLOBE NEWSWIRE) -- Perseon Corporation (PRSN) ("Perseon" or the "Company") today announced the initiation of a multi-organ in vivo ablation zone study for its MicroThermX microwave ablation system designed to provide ablation volumes based on different antenna configurations and varying ablation times in the liver, kidney and lung.

The technology evaluation, which will take place at the University of Louisville, will evaluate both laparoscopic and open surgical approaches with MicroThermX, which are typical treatment regimens for energy ablation. Evaluating ablations in the chosen organs, liver, lung, and kidney, corresponds with today's most common usage for energy ablation.

"The basis for initiating this study was to conduct an analysis of multi-probe MicroThermX' Synchronous Wave Alignment Technology, which is unique in the field of microwave energy ablation," said Robert Martin, MD, PhD, Study Director and Principal Investigator. "The idea that two antennas can be placed in multiple configurations -- not exactly parallel to each other -- and still provide an efficient ablation is a difference maker in a field where ablation zones can vary to great degrees with systems that require precise positioning."

This study is part of Perseon's INSPIRE 2017 campaign, which was created to strengthen the use of microwave ablation in cancer care and gather relevant clinical data to support the movement.

"This trial is pivotal for Perseon, as it marks the first in vivo trial of its kind for MicroThermX," said Brian A. Meltzer, Chief Medical Officer of Perseon. "The push for real world results reinforces our commitment to clinically relevant data and further shows how our Synchronous Wave Alignment Technology provides added efficiency for physicians in the field of energy ablation."

About Perseon Corporation

Related Quotes
PRSN
0.56
+4.13%
Perseon Corporation? Watchlist
0.56+0.02(4.13%)
NASDAQ9:05AM EST

3
http://wsw.com/webcast/rrshq25/prsn/index.aspx

Join the Momentum
Together, we can inspire the world to beat cancer.

With Perseon's MicroThermX® energy ablation device, we have a powerful, life-changing tool that can destroy lung tumors in less than 15 minutes with minimal, if any, side effects.

This revolutionary technology changes everything we thought about how to treat lung tumors. Which is why we need your help. This is your chance to be a part of a momentous change in how cancer is treated.

A chance to change lives by spreading the word.

Inviting Physicians Inviting Patients

Life-Changing Technology
This is the breakthrough we've been waiting for. Doctors are seeing more consistency and effectiveness in their treatments. Patients are enjoying shorter procedures with quicker recoveries. Perseon's MicroThermX energy ablation device is becoming the new standard of care for lung tumors. And we're just beginning to see its true potential.

A patient's life "turned completely around" after being treated: Watch Lance's Story.

for more projects!!

WATCH Perseon's @ Rodman & Renshaw 17th Annual Global Investment Conference 9/10/2015 Presentation here:

wsw.com/webcast/rrshq25/prsn/index.aspx


(You have to manually advance the 32 slides)


<3 PRSN

recent 8K outlook::;

The Letter does not result in the immediate delisting of the Company's common stock, and the stock will continue to trade uninterrupted on the The Nasdaq Capital Market under the symbol "PRSN". The Company intends to resolve the situation to allow for continued listing on The Nasdaq Capital Market.

http://biz.yahoo.com/e/150915/prsn8-k.html

OS 9.8mils from recent filings